Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12906161 | 0.80 | NOTUM (0.59) | NOTUMTSHR | |
| SCHEMBL100765 | 0.80 | HPGDS (0.46) | HPGDS | |
| SCHEMBL28394924 | 0.70 | NOTUM (0.50) | NOTUMTSHR | |
| SCHEMBL497217 | 0.67 | NOTUM (0.44) | NOTUMTSHRNPC1RAB9A | |
| SCHEMBL722557 | 0.65 | LTA4H (0.64) | NOTUMHPGDS | |
| SCHEMBL17694561 | 0.65 | NOTUM (0.78) | NOTUMTSHR | |
| SCHEMBL5820537 | 0.65 | HPGDS (0.34) | HPGDS | |
| SCHEMBL3407358 | 0.65 | NOTUM (0.53) | NOTUM | |
| SCHEMBL26096222 | 0.65 | NOTUM (0.44) | NOTUMTSHRNPC1RAB9A | |
| SCHEMBL6051817 | 0.64 | NOTUM (0.41) | NOTUMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113272293-A | 2-amino-N-heteroaryl-nicotinamide as NAV1.8 inhibitors | 默沙东公司 | 2021-08-17 | — | — | CN | disclosed |
| US-10179131-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170194585-A1 | ORGANIC MIXTURE, FORMULATION AND ORGANIC ELECTRONIC DEVICE COMPRISING THEREOF, AND THEIR APPLICATIONS | GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) | 2017-07-06 | — | — | US | disclosed |
| CN-106822153-A | Method for suppressing amyotrophia | 爱荷华大学研究基金会 | 2017-06-13 | — | — | CN | disclosed |
| US-20170084846-A1 | Liquid Crystal Photoalignment Materials | LOMOX LTD (GB) | 2017-03-23 | — | — | US | disclosed |
| US-20170014408-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-19 | — | — | US | disclosed |
| EP-2637659-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9061030-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| CN-104688745-A | Methods for inhibiting muscle atrophy | UNIV IOWA RES FOUND | 2015-06-10 | — | — | CN | disclosed |
| CN-103037692-B | Methods for inhibiting muscle atrophy | UNIV IOWA RES FOUND | 2015-02-25 | — | — | CN | disclosed |
| CN-104080454-A | Methods for inhibiting muscle atrophy | UNIV IOWA RES FOUND | 2014-10-01 | — | — | CN | disclosed |
| US-20140088071-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20110020566-A1 | Materials | LOMOX LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| EP-1658069-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | Astrazeneca AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005013981-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014408-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | NOTUM 1801/4885TSHR 4250/4885HPGDS 712/4885 |
| US-20140088071-A1 | sGC STIMULATORS | PTGIS, GUCY1B1, GUCY1A1 | NOTUM 3078/4885TSHR 1860/4885HPGDS 16/4885 |
| US-10179131-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | NOTUM 1801/4885TSHR 4250/4885HPGDS 712/4885 |
| US-20110020566-A1 | Materials | VIM, EPCAM, S100A4 | NOTUM 4647/4885TSHR 4680/4885HPGDS 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.